Cancer is a major public health problem. Currently, classification of cancer is based on phenotypic markers. The identification of unique molecular markers of cancer has led to development of new molecular cancer therapies. Movement toward a molecular characterization of cancer would have important clinical benefits, including (1) detecting cancer earlier, (2) predicting risk of precancerous lesion progression, (3) detecting margins in the operating room in real time, (4) selecting molecular therapy rationally and (5) monitoring response to therapy in rear time at a molecular level. Imaging the molecular features of cancer requires molecular-specific contrast agents which can safely be used in vivo as well as cost-effective imaging systems to rapidly and non-invasively image the uptake, distribution and binding of these agents in vivo. Radiographic imaging modalities such as CT and MRI, although useful for delineating the deep extent of advanced carcinomas, are not sufficiently sensitive to detect small, intraepithelial lesions. Optical imaging is a new modality which enables real time, high resolution imaging of epithelial tissue. Optical imaging systems are inexpensive, robust and portable. Optical imaging systems are ideally suited for early detection of intraepithelial disease and to assess tumor margins and response to therapy. The goal of this proposal is to integrate development of optical imaging systems and contrast agents with advances in functional genomics. We will develop molecular-specific, optically active contrast agents that can be applied topically. We will also develop inexpensive, rugged and portable imaging systems to monitor the three-dimensional profile of targeted biomarkers. These contrast agents and imaging systems will have broad applicability to many types of cancer; here, we will develop and test agents and imaging systems for the cervix, oral cavity and the lung, which represent more than 20% of both tumor incidence and mortality worldwide. We will test the safety and efficacy of these contrast agents and imaging systems in animal models, providing data to support phase I and II clinical trials.
The aims of this proposal are to: (1) Develop optically active contrast agents to target four molecular signatures of neoplasia, including EGFR, MMP, telomerase and alpha v integrin; (2) to identify promising new biomarkers for which contrast agents will be developed using SAGE libraries, and to identify promising molecular probes for novel contrast agents using combinatorial methods; (3) to develop inexpensive, portable optical systems to image the morphologic and molecular signatures of neoplasia noninvasively in real time; and (4) to test these agents, delivery formulations and imaging systems in living biological systems of progressively increasing complexity. (5) Our final aim is to integrate these studies to develop a miniature imaging system, which when coupled with the contrast agents developed here, can be used for real time, molecular detection of neoplasia and to monitor, at the molecular level, whether a lesion is responding to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA103830-01
Application #
6701882
Study Section
Special Emphasis Panel (ZRG1-SRB (50))
Program Officer
Baker, Houston
Project Start
2004-08-01
Project End
2005-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$1,561,015
Indirect Cost
Name
University of Texas Austin
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
170230239
City
Austin
State
TX
Country
United States
Zip Code
78712
Liu, Chih-Hao; Nevozhay, Dmitry; Schill, Alexander et al. (2018) Nanobomb optical coherence elastography. Opt Lett 43:2006-2009
Yang, Eric C; Schwarz, Richard A; Lang, Alexander K et al. (2018) In Vivo Multimodal Optical Imaging: Improved Detection of Oral Dysplasia in Low-Risk Oral Mucosal Lesions. Cancer Prev Res (Phila) 11:465-476
Yang, Eric C; Tan, Melody T; Schwarz, Richard A et al. (2018) Noninvasive diagnostic adjuncts for the evaluation of potentially premalignant oral epithelial lesions: current limitations and future directions. Oral Surg Oral Med Oral Pathol Oral Radiol 125:670-681
Haber, Jason; Sokolov, Konstantin (2017) Synthesis of Stable Citrate-Capped Silver Nanoprisms. Langmuir 33:10525-10530
Shadfan, Adam; Darwiche, Hawraa; Blanco, Jesus et al. (2017) Development of a multimodal foveated endomicroscope for the detection of oral cancer. Biomed Opt Express 8:1525-1535
Haber, J M; Gascoyne, P R C; Sokolov, K (2017) Rapid real-time recirculating PCR using localized surface plasmon resonance (LSPR) and piezo-electric pumping. Lab Chip 17:2821-2830
Quang, Timothy; Tran, Emily Q; Schwarz, Richard A et al. (2017) Prospective Evaluation of Multimodal Optical Imaging with Automated Image Analysis to Detect Oral Neoplasia In Vivo. Cancer Prev Res (Phila) 10:563-570
Tang, Yubo; Carns, Jennifer; Richards-Kortum, Rebecca R (2017) Line-scanning confocal microendoscope for nuclear morphometry imaging. J Biomed Opt 22:1-6
Bailey, Maria J; Verma, Nishant; Fradkin, Leonid et al. (2017) Detection of precancerous lesions in the oral cavity using oblique polarized reflectance spectroscopy: a clinical feasibility study. J Biomed Opt 22:65002
Bailey, Maria J; Sokolov, Konstantin (2016) Depth-resolved measurements with elliptically polarized reflectance spectroscopy. Biomed Opt Express 7:2861-76

Showing the most recent 10 out of 75 publications